[
  {
    "ts": null,
    "headline": "Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?",
    "summary": "In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...",
    "url": "https://finnhub.io/api/news?id=0eeb55ad228dce055bf0ffdd643bafefabd2ae30655583660fe5c88f85fcd6af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765066135,
      "headline": "Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)?",
      "id": 137726714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet syndrome and oral macrocyclic peptide research, including positive updates on lecanemab’s subcutaneous formulation and zorevunersen’s long-term effects. The latest findings suggest Biogen is deepening its presence in high-need neurological conditions with therapies that aim not only to relieve...",
      "url": "https://finnhub.io/api/news?id=0eeb55ad228dce055bf0ffdd643bafefabd2ae30655583660fe5c88f85fcd6af"
    }
  }
]